| Audience | Adults with type 2 diabetes considering injectable treatment, families, primary-care clinicians, endocrinology clinicians, and readers following GLP-1 research |
| Primary Topic | IcoSema and type 2 diabetes |
| Source | Read the full source |
Once-Weekly IcoSema for Type 2 Diabetes: What COMBINE 4 Found
A 485-person randomized phase 3b trial found that once-weekly IcoSema lowered HbA1c and body weight more than once-daily insulin glargine, with fewer clinically significant or severe hypoglycemia episodes. The open-label, sponsor-funded trial does not establish long-term cardiovascular benefit, comparative value against separate modern GLP-1 regimens, or current approval.
| Study Type | Open-label, multicenter, treat-to-target, randomized phase 3b trial |
| Population | 485 insulin-naive adults with type 2 diabetes inadequately controlled on oral glucose-lowering medicines |
| Setting | 97 sites across nine countries |
| Intervention | Once-weekly subcutaneous IcoSema, a fixed combination of insulin icodec and semaglutide |
| Comparator | Once-daily subcutaneous insulin glargine U100 |
| Duration | 40 weeks, with adverse events recorded through week 45 |
| Primary Outcome | Change in HbA1c from baseline to week 40 |
| Primary Result | -3.32 percentage points with IcoSema versus -2.44 with glargine; estimated treatment difference -0.88 points, 95% CI -1.12 to -0.63 |
| Body-Weight Result | -0.79 kg with IcoSema versus +3.81 kg with glargine; estimated treatment difference -4.61 kg, 95% CI -5.46 to -3.75 |
| Hypoglycemia Result | 0.29 versus 0.59 clinically significant or severe episodes per person-year; rate ratio 0.56, 95% CI 0.32 to 0.97 |
| Adverse Events | Gastrointestinal disorders were most frequent with IcoSema |
| Journal | The Lancet Diabetes & Endocrinology |
| Published | August 13, 2026 |
| PMID / DOI | 42594928 / 10.1016/S2213-8587(26)00136-1 |
| Major Limitation | Open-label design, 40-week duration, treat-to-target protocol, investigational product, and Novo Nordisk funding |
Mean HbA1c fell by 3.32 percentage points with IcoSema and 2.44 points with glargine at week 40.
The between-group estimate favored IcoSema by 0.88 percentage points, but the treat-to-target design and open-label treatment should remain part of the interpretation.
Mean body weight decreased by 0.79 kg with IcoSema and increased by 3.81 kg with glargine.
This reflects the tested fixed combination. It should not be used to infer how every insulin and GLP-1 pairing will perform.
The rate of clinically significant or severe hypoglycemia was 0.29 episodes per person-year with IcoSema and 0.59 with glargine.
The confidence interval for the rate ratio was 0.32 to 0.97, so the result favored IcoSema but remained less precise than the HbA1c estimate.
Gastrointestinal disorders were the most frequently reported adverse events with IcoSema, consistent with semaglutide exposure.
The abstract does not provide every event count or discontinuation detail, so tolerability should not be reduced to the hypoglycemia result alone.
IcoSema combines once-weekly insulin icodec with semaglutide in a fixed formulation and was investigational in the trial record.
The study does not establish approval in every jurisdiction, affordability, real-world adherence, cardiovascular-event reduction, or superiority to separately titrated components.
Fixed-ratio insulin and GLP-1 combinations aim to simplify treatment while balancing glycemic control, weight, and hypoglycemia. A weekly formulation may reduce injection frequency, but convenience, persistence, access, and cost require direct real-world measurement.
For patients, the relevant comparison is not simply weekly versus daily. Baseline HbA1c, hypoglycemia risk, gastrointestinal tolerance, kidney and cardiovascular disease, medication access, and the ability to titrate each component all influence clinical fit.
I read COMBINE 4 as a strong randomized signal that this specific weekly combination can improve glucose control while avoiding the weight gain often seen with basal insulin initiation. That is useful, but it is not the same as proving that one fixed combination is best for every patient.
The patient-level question remains whether the formulation’s dosing, titration, adverse effects, approval status, access, and long-term evidence fit the individual better than established alternatives.
How to Read a Positive Open-Label Diabetes Trial
The randomized active-comparator result is clinically meaningful.
Its reach is limited by duration, treatment structure, product status, and sponsor involvement.
Four distinctions that matter
Glycemic efficacy versus long-term outcomes
A 40-week HbA1c benefit does not establish cardiovascular-event reduction, mortality benefit, or durability over years.
Fixed combination versus separate components
The trial tested IcoSema as one product, not every way of combining basal insulin and semaglutide.
Randomized versus blinded
Randomization reduces allocation bias, while open-label treatment can still influence behavior, reporting, and treatment management.
Trial result versus availability
Peer-reviewed phase 3b evidence does not by itself establish regulatory approval, coverage, or access in a given jurisdiction.
The Same Study Can Mean Different Things Depending on the Question Being Asked
Scientific papers rarely answer a single question. Patients, clinicians, researchers, policymakers, and critics often read the same data differently. The perspectives below explore how this study looks through several evidence-based lenses.
A Weekly Option Is Not Automatically the Right Option
The trial suggests fewer injections and favorable average glucose and weight outcomes with IcoSema.
Personal fit still depends on approval, access, gastrointestinal tolerance, hypoglycemia risk, and treatment goals.
Concordant Efficacy and Safety Signals
HbA1c, body weight, and hypoglycemia all favored IcoSema in the randomized comparison.
The fixed-ratio format limits separate titration of its insulin and semaglutide components.
Open-Label and Sponsor-Funded
Open-label treatment can affect reporting and management even when endpoints include laboratory measures.
Novo Nordisk funding makes full reporting and independent confirmation particularly important.
Forty Weeks Is Not Long-Term Outcomes Evidence
The study was long enough to measure HbA1c and weight but not cardiovascular events or multi-year durability.
Adverse-event interpretation also needs full event and discontinuation data.
A New Comparison in the IcoSema Program
Earlier COMBINE trials compared IcoSema with other insulin strategies.
COMBINE 4 specifically addresses insulin-naive adults starting injectable intensification against daily glargine.
Injection Frequency Is Only One Burden
Weekly dosing may be attractive, but affordability, storage, titration, nausea, coverage, and follow-up also shape persistence.
The trial did not establish real-world adherence or cost-effectiveness.
Durability and Real-World Use Come Next
Longer follow-up should assess persistence, cardiovascular and kidney outcomes, uncommon harms, and outcomes after discontinuation.
Comparisons with separately titrated modern regimens would clarify flexibility and value.
Approval and Coverage Must Be Named Precisely
Publication does not establish that IcoSema is approved, covered, or available in every jurisdiction.
Public communication should separate development evidence from current prescribing status.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan
Want to discuss this topic with other patients and caregivers? Join the forum discussion
When a new paper overlaps with earlier CED Clinic coverage, we preserve the chain instead of hiding the overlap. These links point to older related posts so readers can compare what is new, what is repeated, and how the evidence has moved.
The Foundayo clinical trial provides important data on GLP-1 therapy for type 2 diabetes patients with cardiovascular risk. This trial compares Foundayo against insulin glargine, highlighting efficacy and safety. Clinic…
Frequently Asked Questions
What did COMBINE 4 test?
It compared once-weekly IcoSema with once-daily insulin glargine U100 for 40 weeks in 485 insulin-naive adults with type 2 diabetes inadequately controlled on oral medicines.
What is IcoSema?
IcoSema is a fixed-ratio combination of once-weekly insulin icodec and the GLP-1 analogue semaglutide.
How did HbA1c change?
Mean HbA1c fell by 3.32 percentage points with IcoSema and 2.44 points with glargine at week 40.
How did body weight change?
Mean body weight decreased by 0.79 kg with IcoSema and increased by 3.81 kg with glargine.
What happened with hypoglycemia?
Clinically significant or severe hypoglycemia occurred at 0.29 episodes per person-year with IcoSema and 0.59 with glargine.
What adverse events were most common?
The abstract reports gastrointestinal disorders as the most frequently reported adverse events with IcoSema.
Was the trial blinded?
No. It was randomized but open-label, so participants and investigators knew the assigned treatment.
Does the trial prove cardiovascular benefit?
No. COMBINE 4 measured glycemic, body-weight, and safety outcomes, not cardiovascular-event or mortality benefit.
Is IcoSema approved everywhere?
No conclusion about universal approval or availability follows from this publication. Regulatory and prescribing status must be checked by jurisdiction.
What is the practical takeaway?
IcoSema showed a strong 40-week product-specific signal compared with glargine, but treatment decisions still require individual assessment of risks, benefits, access, and approved options.
